MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Losartan Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Not Applicable
Recruiting
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2024-03-25
Last Posted Date
2024-04-11
Lead Sponsor
University of Electronic Science and Technology of China
Target Recruit Count
80
Registration Number
NCT06329076
Locations
🇨🇳

University of Electronic Science and Technology of China, Chengdu, Sichuan, China

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Phase 1
Recruiting
Conditions
Locally Recurrent Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Refractory Head and Neck Squamous Cell Carcinoma
Interventions
Radiation: Stereotactic Body Radiation Therapy
First Posted Date
2024-01-18
Last Posted Date
2025-04-18
Lead Sponsor
Shyam S.D. Rao
Target Recruit Count
24
Registration Number
NCT06211335
Locations
🇺🇸

University of Colorado Denver | Anschutz Medical Campus, Aurora, Colorado, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

Phase 3
Recruiting
Conditions
Coarctation of Aorta
High Blood Pressure
Interventions
First Posted Date
2023-11-29
Last Posted Date
2024-07-29
Lead Sponsor
Mayo Clinic
Target Recruit Count
120
Registration Number
NCT06150560
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Phase 2
Completed
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
First Posted Date
2023-11-18
Last Posted Date
2025-04-24
Lead Sponsor
Future University in Egypt
Target Recruit Count
84
Registration Number
NCT06135493
Locations
🇪🇬

Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University, Cairo, Egypt

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

Phase 1
Recruiting
Conditions
Knee Arthroplasty, Total
Interventions
First Posted Date
2023-10-30
Last Posted Date
2024-03-12
Lead Sponsor
Steadman Philippon Research Institute
Target Recruit Count
120
Registration Number
NCT06108063
Locations
🇺🇸

The Steadman Clinic, Vail, Colorado, United States

Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients

Phase 2
Recruiting
Conditions
Colorectal Cancer
Oral Mucositis
Chemotherapy
Intestinal Mucositis
Interventions
First Posted Date
2023-05-23
Last Posted Date
2023-07-19
Lead Sponsor
Ain Shams University
Target Recruit Count
80
Registration Number
NCT05871333
Locations
🇪🇬

Hospital, Cairo, Egypt

GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

Phase 2
Withdrawn
Conditions
Pancreatic Cancer
Interventions
Radiation: Stereotactic Body Radiation Therapy
First Posted Date
2023-05-16
Last Posted Date
2024-12-27
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
34
Registration Number
NCT05861336
Locations
🇮🇹

U.O. Radioterapia IRCCS IRST, Meldola, Forlì, Italy

🇮🇹

UO Oncologia, AUSL della Romagna, Ravenna, Italy

A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome

Phase 4
Not yet recruiting
Conditions
Essential Hypertension
Metabolic Syndrome
Interventions
First Posted Date
2023-05-06
Last Posted Date
2023-05-06
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
116
Registration Number
NCT05843162

Losartan and Memory

Not Applicable
Completed
Conditions
PTSD
Interventions
First Posted Date
2023-04-25
Last Posted Date
2023-04-27
Lead Sponsor
University of Oxford
Target Recruit Count
41
Registration Number
NCT05828940
Locations
🇬🇧

Department of Psychiatry, University of Oxford, Oxford, United Kingdom

Azilsartan in Patients With Diabetic Kidney Disease and Hypertension

Not Applicable
Recruiting
Conditions
Proteinuria
Kidney Dysfunction
Diabetic Kidney Disease
Blood Pressure
Interventions
First Posted Date
2023-03-03
Last Posted Date
2023-03-03
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
106
Registration Number
NCT05753696
Locations
🇨🇳

the Second Afficiated Hospital, Zhejiang University, School of Medicine, Hanzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath